Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 12,288

Document Document Title
WO/2017/103109A1
The present invention relates to a polymorph of a compound of formula (I) This polymorph is particularly suitable in treating IPF by pulmonary administration.  
WO/2017/097973A1
The present invention relates to modified nucleosides which are linked to cargo molecules and which can be incorporated by DNA or RNA polymerases in strand synthesis. The present invention also relates to use of such modified nucleosides...  
WO/2017/098252A1
The present invention provides a method for the preparation of intermediates useful in the synthesis of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. It also provides a method of preparing gemcitabine-[phenyl-benzoxy-L-alaninyl)]-p...  
WO/2017/093973A1
The present invention provides pure sofosbuvir and a process for the preparation of pure sofosbuvir and its intermediates.  
WO/2017/094011A1
The present invention relates to pharmaceutically acceptable salts of conjugates comprising a chemotherapeutic drug and an amino acid or a derivative thereof, which are readily taken up by a target cell and reduce side effects induced by...  
WO/2017/093317A1
A method for the mobilization of a transposable element is provided. The method comprises the steps of a) providing an inhibitor of DNA methylation, and/or an inhibitor of transcription, and b) contacting the inhibitor(s) with a cell com...  
WO/2017/096246A1
The present invention encompasses compositions and methods for regulating the kynurenine to tryptophan ratio, NAD+ level and CD16 expression for the treatment diseases.  
WO/2017/090275A1
[Problem] To provide a drug that substitutes for injections (5-azacytidine or 2'-deoxy-5-azacytidine) that are clinically used as bone marrow tumor therapeutic drugs, said drug having high stability with respect to metabolic enzyme cytid...  
WO/2017/090264A1
[Problem] To provide a drug that substitutes for injections (5-azacytidine or 2'-deoxy-5-azacytidine) that are clinically used as bone marrow tumor therapeutic drugs, said drug having high stability with respect to metabolic enzyme cytid...  
WO/2017/087517A1
The invention relates to nucleotide prodrugs and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel prodrugs of the invention.  
WO/2017/087887A1
This disclosure is related to a method for determining the identity of a nucleotide residue of a single-stranded DNA or RNA, or sequencing DNA or RNA, in a solution using an ion-sensing field effect transistor and reversible nucleotide t...  
WO/2017/086397A1
Provided is a novel method for producing an oligonucleotide using a nucleoside or oligonucleotide that is easy to isolate and has high storage stability. A method for producing an oligonucleotide including a step for carrying out H-phosp...  
WO/2017/080973A1
The present invention relates to a compound of the general formula (1). wherein A is selected from a group of formula 2. B is selected from a group of formula 3. The compound of formula (1) is suitable for use in a method for treating a ...  
WO/2017/079195A1
Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, and compositions comprising such compounds that are useful for increasing the amount of NAD+ in cells. Also disclosed are methods of using the d...  
WO/2017/076266A1
The present invention relates to a method for preparing (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-((2-(methylthio)ethyl)a mino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahyd rofuran-3,4-diol. Specifically, the present invention relat...  
WO/2017/077552A1
A process for the preparation of intermediates 9, useful in the synthesis of sofosbuvir, as well as intermediates of formula [12] are disclosed herein.  
WO/2017/079745A1
Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human.  
WO/2017/070464A1
Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure (I) They are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.  
WO/2017/066791A1
The present disclosure relates to cap analogs of formula (I), which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for prepar...  
WO/2017/066571A1
Provided are methods and compositions for treating cancers in patients carrying an IDHl mutation using a combination of an inhibitor of a mutant IDHl enzyme and a DNA demethylating agent.  
WO/2017/066566A1
Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using a combination of an inhibitor of a mutant IDH1 enzyme and an AML induction and consolidation therapy.  
WO/2017/066793A1
The present disclosure relates to cap analogs of formula (I) as defined in claim 1, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to met...  
WO/2017/066782A1
The present disclosure relates to cap analogs of formula (I), which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for prepar...  
WO/2017/059249A1
The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterin...  
WO/2017/058953A1
Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof in the sequencing a nucleic acid.  
WO/2017/053216A2
The present invention is directed to 4'-substituted nucleoside derivatives of Formula (I) and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the proph...  
WO/2017/045583A1
Provided is a preparation method of composition rich in compound Sp-1. The method performs isomer separation on a reaction product from a first step, and then performs a two-step chemical synthesis, so as to prepare a composition compris...  
WO/2017/045582A1
Provided in the present invention are a novel preparation method of nucleoside phosphoramidate prodrugs and intermediates thereof. In particular, the method is adopted to perform isomer separation on a reaction product from a first step ...  
WO/2017/048147A1
The object of the invention is a method of synthesis and purification of a nucleoside and/or a nucleotide being a mono-, di- or triphosphate, wherein a Huisgen' s azide-alkyne cycloaddition reaction is being performed using a compound of...  
WO/2017/045581A1
The present invention involves a composition rich in compound 61501b, wherein the compound 61501b has a purity not less than 90% or more. The composition has a significant advantage in preparing high-purity compound Sp-1. In addition, th...  
WO/2017/047816A1
The present invention provides a method for producing guanidine crosslinked artificial nucleic acid (abbreviated hereinafter as GuNA), and an intermediate compound for the production thereof. Specifically, the present invention provides ...  
WO/2017/042038A1
The present disclosure relates to compositions and methods based on polypeptide-tagged nucleotide, and the use of such polypeptide-tagged nucleotides in nanopore devices and methods.  
WO/2017/040896A1
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...  
WO/2017/040766A1
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...  
WO/2017/040895A1
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...  
WO/2017/040898A1
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...  
WO/2017/036356A1
Provided are a new crystal form of Fludarabine Phosphat, a preparation method therefor, a pharmaceutical composition containing same, and an application thereof in preparing medicine. Crystal forms I and II of the Fludarabine Phosphat ha...  
WO/2017/040892A1
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...  
WO/2017/040899A2  
WO/2017/040889A1
The present invention features compounds effective in inhibiting active against Hepatitis C virus ("HCV") polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of ...  
WO/2017/035453A1
The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for treating solid tumors. In a specific embodiment, a method for treating a solid tumor in a patient...  
WO/2017/031278A1
The present disclosure relates to processes for inverting oligonucleotide probes in an in situ synthesized array. These processes can be used to reverse the orientation of probes with respect to the substrate from 3 '-bound to 5 '-bound....  
WO/2017/027980A1
There is provided a method for treating or preventing a Neisseria gonorrhoeae infection in a subject, comprising administering to the subject an effective amount of a compound of general formula I below or a pharmaceutical composition co...  
WO/2017/029408A1
Disclosed are solid state forms of sofosbuvir. The solid state forms may be co-crystals of sofosbuvir with at least one co-crystal former.  
WO/2017/031189A1
The invention provides compositions and methods for the production of TDP-deoxysugars.  
WO/2017/023687A1
In one aspect, the present invention features a method of inhibiting proliferation and/or reducing survival of a cell comprising a GNAQ polynucleotide or polypeptide having a R183Q or Q209L mutation, comprising contacting the cell with p...  
WO/2017/024310A1
The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also pr...  
WO/2017/023694A1
This invention relates the use of Cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neop...  
WO/2017/019581A1
The present invention is directed to processes for making Compounds of Formula (IV): (IV) and salts thereof, wherein B, X, R1, R2, R3 and R4 are defined herein.  
WO/2017/018360A1
Provided is an artificial nucleoside, or artificial nucleotide, that is a compound represented by formula (I) or a salt thereof. In formula (I), Bx is a pyrimidine base, thioxopyrimidine base, or purine base, R1, R2, R3 and R4 are hydrog...  

Matches 301 - 350 out of 12,288